Health-care companies rose, but not by as much as the broad market, amid skepticism about growth prospects for the sector.

Eli Lilly shares fell after the drug giant's Alzheimer's drug was rejected by the Food and Drug Administration.

Defensive issues such as health insurer UnitedHealth Group, which far surpassed the performance of the broad stock market last year, are lagging in 2023 as cyclical sectors rebound.


Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

01-20-23 1656ET